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1. Introduction 
Septic shock is an acute cardiovascular collapse result- 
ing from the systemic response to a bacterial infection, 
and is manifested by hypotension, a lack of response to 
vasoconstrictors, tissue damage and multi-organ failure 
[l]. Despite intensive studies, the mechanisms underlying 
sepsis and septic shock are not yet known. 
The overproduction of nitric oxide PNO), a diffusible 
free radical, identified in recent years as a potent en- 
dogenous vasodilator, has been implicated as the basis 
for hypotension and the lack of response to vasocon- 
strictors during septic shock [2,3]. Intravenous admini- 
stration of lipopolysaccharide (LPS; bacterial endotoxin) 
produced septic-shock like syndrome in animals and hu- 
mans [4,5]. Reversal of LPS-induced hypotension in ani- 
mals was observed following intravenous injection of 
NG-monomethyl+arginine (NMMA), an inhibitor of ni- 
tric oxide synthases [6,7]. 
In blood, *NO reacts with oxyhemoglobin to yield 
nitrate and methemoglobin [S]. Elevated plasma and uri- 
nary nitrate levels therefore serve as indirect evidence for 
the overproduction of *NO in cytokine-induced and sep- 
tic shock in animals and humans [9-l 11. Additionally, 
low-temperature EPR detection of nitrosylated hemo- 
globin (HbNO) in blood has been used for assessing *NO 
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A nitric oxide eN0) spin-trapping technique combined with electron paramagnetic resonance (EPR) spectroscopy has been employed to measure 
the in viva production of *NO in lipopolysaccharide (LPS)-treated mice. The in vivo spin-trapping of *NO was performed by injecting into mice a 
metal-chelator complex, consisting of N-methyl-Dglucamine dithiocarbamate (MGD) and reduced iron (Fe*‘), that binds to *NO and forms a 
stable, water-soluble [(MGD),-Fe’+-NO] complex, and by monitoring continuously the in vivo formation of the latter complex using an S-band EPR 
spectrometer. At 6 h after intravenous injection of LPS, a three-line EPR spectrum of the [(MGD)z-Fe2’-NO] complex, was observed in the blood 
circulation of the mouse tail, the [(MGDkFe27 complex was injected subcutaneously 2 h before EPR measurement. No signal was detected in control 
groups. Administration of fl-monomethyl-L-arginine, an *NO synthase inhibitor, caused a marked reduction in the in vivo EPR signal of the 
[(MGD),-Fe*+-NO] complex, suggesting that the *NO detected is synthesized via the arginine-nitric oxide synthase pathway. The results presented 
here demonstrated, for the first time, the in vivo real time measurement of aNO in the blood circulation of conscious, LPS-treated 
animals. 
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production in septic shock [12,13] and in allograft rejec- 
tion 141. However, none these methods 
vivo measurement *NO. 
Recently have described 
vivo measurement 
blood circulation [15]. The 
method is based 
(MGD) and reduced iron to 
a stable, water-soluble [(MGD),-Fe2+-NO] 
whose characteristic three-line spectrum 
spec- 
troscopy 
have *NO spin-trapping technique to meas- 
real *NO production LPS- 
treated mice. 
2. Materials 
mice (female, 25-30 g) supplied 
IN). Animals were free access to water, 
but not for 24 h before the experiment. Lipopolysaccharide (LPS; 
E. 026:B6) from Sigma (St. Louis, MO). 
from Calbiochem (San Diego, CA). 
were obtained from 
WI). *NO gas was purchased from 
pure argon from Airco (Murray Hill, 
A saturated water was prepared 
Kehn and Schrader [161. The concentration of the saturated 
*NO solution at 22°C is 2.0 mM, as verified by an ISO-NO meter from 
World Precision Instruments (Sarasota, FL). Methoxyflurane was from 
Pitman-Moore Inc (Mundelein, IL). Sodium pentobarbital was from 
Anpro Pharmaceutical (Arcadia, CA). NO; was measured by a colori- 
metric assay [17]. NO; was first converted to NO; by E. coli nitrate 
reductase [18] and measured as described above. N-methyl-o-ghuzamine 
All rights reserved. 
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dithiocarbamate (MGD) was synthesized by following the method of 
Shinobu et al. [19]. Element analysis for C,H,,NOsS,Na* 1 HsO: Calcu- 
lated: C,30.83; H5.78; N,4.50; 0,30.83; S,20.56; Na,7.39; found: 
C,31.01; H,6.23; N,4.40; 0,30.17; S,19.65; Na,7.57 (Galbraith Lab, 
Knoxville, TN). 
2.1. EPR measurement 
The EPR spectra were recorded with an EPR spectrometer, equipped 
with an S-band microwave bridge and a low-frequency loopgap reso- 
nator with a 4-mm loop, operating at 3.5 GHx [20]. After i.v. injection 
of LPS (0.6 mg to 6 mg per animal) via the lateral tail vein, mice were 
anesthetized with methoxyllurane prior to subcutaneous injections with 
0.4 ml of the [(MGD)r-Fe27 complex in water (326 mg/kg of MGD and 
34 mg/kg of FeSO,,) at 0,2,4,6 or 8 h; at least three separate xperi- 
ments in each group. The mouse housed in a plexiglass restraining tube 
was transferred to the S-band EPR spectrometer. The tail of the mouse 
was immobilized by taping down with a thin and narrow plexiglass tick 
and then placed inside the resonator. The reason that the S-band EPR 
spectrometer was chosen in this in vivo experiment is because the 
diameter of the tip region of the mouse tail (about 2-3 mm) fits well 
with the 4-mm loop of the S-band loop-gap resonator. The animal 
remained conscious in the restraining tube for in vivo EPR experiments 
as well as all other experiments reported in this study; no anesthetic 
agent was used. The in vivo EPR signal was recorded at 2 h after the 
injection of the [(MGD)r-Fe”] complex. For inhibition experiments, at 
6 h after LPS treatment, mice were injected intraperitoneally with an 
aliquot solution of NMMA in saline (50 mg/kg). Animals were sacri- 
ficed and the tissue samples including whole blood, liver and kidney 
were transferred into quartz tubes (i.d., 2 mm) for EPR measurement 
at room temperature. Instrument settings include 100 G field scan, 30 s 
scan time, 0.1 s time constant, 2.5 G modulation amplitude, 100 kHx 
modulation frequency and 25 mM microwave power [15]. 
2.2. Surgical preparation 
All surgical procedures were approved by the Medical College of 
Wisconsin Animal Care Committee and the animals were closely mon- 
itored to insure that none experienced any undue stress or discomfort. 
The mice were anesthetized with sodium pentobarbital(50 mg/kg, i.p.) 
and maintained at a stable depth of anesthesia with supplemental doses 
and/or (1%) methoxytlurane as required [ 151. They were placed on a 
heated surgical table and chronic indwelling catheters were inserted into 
the femoral artery and vein. All mice were fully awake and experienced 
no apparent discomfort when they were returned to the Animal Re- 
source Center. 
2.3. Hemodynamic measurement 
Measurement of blood pressure and heart rate were made on con- 
scious mice from 1 to 14 days after surgery [ 151. The mice were trained 
to sit quietly in a plexiglass restraining tube for all blood pressure 
measurements. Blood pressure was measured using a solid-state pres- 
sure transducer (Cobe Laboratories, Lakewood, CO), and a general 
purpose amplifier. The data were collected at 200 Hx by microcomputer 
using data acquisition software (DATAQ Instruments Inc., Akron, 
OH). 
3. Results and discussion 
The bolus infusion of LPS (6 mglmouse) into the 
catheterized mouse femoral vein resulted in a gradual fall 
in mean arterial pressure from 121 f 3 mmHg to 85 + 7 
mmHg within 6 h as measured form the catheterized 
femoral artery. This suggests that the LPS-treated mice 
were in septic-shock-like conditions after the lethal dose 
of LPS administration; none of the LPS-treated mice 
survived over 24 h. 
For in vivo EPR experiments, after LPS administra- 
tion (6 mg/mouse), the mice were injected subcutane- 
ously with an aqueous solution (0.4 ml) containing the 
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Fig. 1. 3.5 GHx EPR spectra of the [(MGD)s-Fe’+-NO] complex in the 
circulation of the mouse tail at various times after LPS administration. 
After intravenous injection of LPS (6 mg; E. coli 0.26:B6) through the 
lateral tail vein, an aliquot (0.4 ml) of [(MGD)r-Fez’] complex in water 
was injected subcutaneously at (a) 0 h, (b) 2 h, (c) 4 h, and (d) 6 h. 
(e) Before the injection of the [(MGD)2-Fez+] complex at 6 h as in (d), 
an aliquot of NMMA in saline (50 mg/kg) was injected intraperitone- 
ally. The concentrations of MGD and FeSO, in the injected solution 
were 83.3 mM and 16.7 mM, respectively. All spectra were recorded 2 
h after the injection of the [(MGD)s-Fe*‘] complex. Each of the spectra 
presented here was an average of nine 30 s scans. 
spin-trapping reagent, the [(MGD)z-Fe2’] complex, at 
either 0,2,4, or 6 h, respectively. The in vivo EPR signal 
was recorded 2 h after injection of the [(MGD)2-Fe2+] 
complex, i.e. at 2,4, 6, or 8 h after LPS. The results are 
shown in Fig. 1. While no signal was detected at 2 or 4 h 
(Fig. la,b), a three-line EPR spectrum of the [(MGD)2- 
Fe2+-NO] complex (a” = 12.5 G, and g, = 2.04), was 
observed at 6 h (Fig. lc). The signal intensity was further 
increased at 8 h after LPS administration as shown in 
Fig. Id. No EPR signal was detected in control mice 
injected only the [(MGD),-Fe27 (data not shown). A 
weak EPR signal of the [(MGD)2-Fe2+-NO] complex was 
detected when the mouse was administrated with LPS at 
a dose of 0.6 mg per mouse. The dosage of 6 mg per 
mouse was used for the rest of the data reported in this 
study. Thus, the results here provide direct in vivo evi- 
dence that *NO is produced in LPS-treated conscious 
mice, as demosntrated in Figure lc and Id. 
The observed 6 h delay for the appearance of the 
[(MGD),-Fe’+-NO] complex in the circulation (Fig. l), 
agrees well with the time that is required for the induc- 
tion of the inducible *NO synthase in vascular endothe- 
lium after LPS challenge [21-231, as well as with the 
observed time-dependent drop in mean arterial pressure 
in the LPS-treated mice as described above. Interest- 
ingly, when NMMA (50 mg/kg) was injected at 6 h after 
LPS administration, the EPR signal intensity was re- 
duced by more than one-half (Fig. le), a result further 
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Fig. 2. Time course of in vivo EPR signal intensities of the [(MGD),- 
Fe”-NO] complex in mouse tail circulation during septic shock. Six h 
after intravenous injection of LPS (6 mg; E. coli 026B6) as described 
in part (d) of Fig. 1, and aliqudt (0.4 ml) of the [(MGD)rFes’] complex 
in water was injected subcutaneously, and the EPR signal was recorded 
immediately and followed for a period of 4 h. Normalized data points 
obtained from three separate xperiments (r, 0, and n ) were shown. 
confirming that the observed lN0 production was via the 
arginine-NO synthase pathway [6,7]. 
Data on serum NO; levels in the LPS-induced shock 
mice are summarized in Table 1, in which the LPS treat- 
ment was shown to produce a nine-fold increase in the 
blood NO; levels. As expected, the administration of the 
[(MGD)2-Fe2’] complex, which traps *NO to form a sta- 
ble [(MGD),-Fe2+-NO] complex, reduced the blood NO; 
levels in the LPS-treated mice. The NO; levels in the sera 
with or without LPS administration were below 1 /.LM 
and beyond detection by the Griess reaction (data not 
shown), which is different from our previous work, in 
which we reported that the serum of control normal mice 
contained 11.8 + 2.2 ,uM NO; [15]. This difference in 
NO, level may be ascribed to that in the previous work 
Table 1 b. 
Effects of LPS and the [(MGD)z-Fe2+] complex on nitrate concentra- 
tions in mouse sera’ 
Condition NO; GM) 
Control 
LPS” 
LPS + [(MGD)2-Fe2+]b 
62.6 f 5.8 (5) 
586.4 f 47.4 (3)* 
336.3 f 45.9 (3)** 
*Mice were sacrificed 8 h after intravenous LPS injection (6 mg; E. coli 
026B6). 
b Mice received subcutaneous injection of the [(MGD)s-Fe*‘] complex 
six hours after LPS injection were sacrificed 2 h later. *P < 0.05 com- 
pared to control. **P < 0.05 compared to the LPS- treated group. 
‘The data presented are mean ? S.E.M. (number of mice). 
the mice were fed, and in the present study the mice were 
fasted for 24 h prior to experiments. 
The time course for the appearance of the in vivo EPR 
signal of the [(MGD),-Fe2+-NO] complex in the blood 
circulation of the 6 h LPS-treated mice is shown in Fig. 
2. No signal was detected until about 45 min after subcu- 
taneous injection of the [(MGD)2-Fe2’] complex, and 
then the signal incrased with time and reached a plateau 
at about 4 h, at which the equilibrium appeared to be 
reached between the formation and the clearance of the 
[(MGD)2-Fe2’-NO] complex in the blood. All EPR data 
reported in this study were recorded at 2 h after subcuta- 
neous injection of the [(MGD)2-Fe2’] complex. To inves- 
tigate the tissue distribution of the [(MGD),-Fe’+-NO] 
complex, we sacrificed the 6 h LPS-treated mice and 
recorded the EPR signal in various tissues. The 
[(MGD)2-Fe2’-NO] complex was shown to be present in 
liver, kidney and whole blood (Fig. 3), which is in agree- 
ment with the data reported previously by other investi- 
gators using diethyldithiocarbamate (DETC) as a spin- 
trapping reagent in which they detected the presence of 
the [(MGD)2-Fe2’-NO] complex in various tissues [24]. 
Among all tissues examined thus far, the liver tissue 
retained the highest EPR signal intensity of the 
[(MGD),-Fe”-NO] complex (Fig. 3 and Table 2). The 
concentration of the [(MGD)2-Fe2’-NO] complex in Fig. 
3a was about 20 ,uM. The presence of the signal in iso- 
lated whole blood also confirms that the EPR signals in 
Fig. lc and d are due to the [(MGD),-Fe2’-NO] complex 
circulating in the blood rather than trapped in the tail 
region, although it is possible that some of the detected 
signal is attributable to the [(MGD),-Fe2’-NO] complex 
formed in the endothelium and smooth muscle of the tail 
region. 
a. 
c. 
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Fig. 3. 3.5 GHz EPR spectra of the [(MGD)2-F$‘-NO] complex in 
various tissues of the septic-shock mouse. The experimental conditions 
were the same as described in Fig. 2, except hat septic-shock mice were 
sacri6ced 8 h after LPS administration. Isolated (a) liver tissue (89 mg, 
wet weight), (b) kidney tissue (74 mg, wet weight) and (c) heparinized 
whole blood (100 ,rd) were transferred into quartz tubes (i.d. 2 mm) for 
EPR measurement at 22V. Each of spectra presented here was an 
average of nine 30 s scans. 
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Fig. 4. Time course of EPR signal intensities of the [(MGD)2-FeZ+-NO] 
complex in isolated liver and kidney tissues after intravenous injection 
of LPS. After intravenous injection of LPS (6 mg; E. coli 026:B6), the 
mice were injected subcutaneously with an aliquot (0.4 ml) of the 
[(MGD)r-Fe*‘] complex at 0,2,4,6, or 8 h. The animals were sacrificed 
two hours after each time point of the injection of the complex, and the 
liver (0) and kidney 0 tissues were transferred to quartz tubes for 
EPR measurement. The averaged wet weights of liver and kidney tissue 
sample were 88 + 3 and 81 f: 4 mg, respectively, which correspond to 
59 and 61 mg after corrections for the blood present in these tissues [26]. 
The data presented are averages of three separate xperiments. 
Fig. 4 shows the time-dependent EPR signal intensities 
of the [(MGD),-Fe’+-NO] complex in the liver and kid- 
ney tissues after i.v. injection of LPS and subcutaneous 
injection of the [(MGD)z-Fe2’] complex. The signal in- 
tensity in the liver appeared to peak at 6 h after LPS 
administration, and then decreased with time (Fig. 4, 
closed circles). This is consistent with a 6 h delay in the 
LPS-induced NO; generation in vivo [21-231, and the 
time course of the in vivo EPR signals as shown in Fig. 
1. On the other hand, the signal intensity in the kidney 
tissue increased slowly with time; no maximum was 
noted (Fig. 4, closed triangles). Previously, using sodium 
nitroprusside (SNP) as an *NO dodnor and the 
[(MGD),- Fe’+] complex as an *NO spin-trapping rea- 
gent, we showed that the in vivo EPR signal of the 
[(MGD),-Fe”- NO] complex formed in the blood circu- 
lation of the mouse increased with time and reached a 
maximum at 19 + 3 min, and then decayed with a fl12 of 
about 15 min [15]. In contrast, in the present study, the 
in vivo EPR signal of the [(MGD),-Fe2+-NO] complex 
detected in the blood circulation of the LPS-induced 
shock mouse as shown in Fig. 2 increased over at least 
4 h and plateaued for several additional hours or until 
the animal died. This apparent discrepancy may be due 
to the differences in ways by which the [(MGD),-Fe2’] 
complex was injected. In the previous study, the 
[(MGD)2-Fe2’] complex was injected intravenously, 
where it reacted with *NO released from SNP to form the 
[(MGD),-Fe’+-NO] complex; the latter was then cleared 
from the circulation within an hour [ 151. We also injected 
the [(MGD)2-Fe2+- NO] complex intravenously into the 
normal control mice, and found that the complex was 
excreted into the urine within 30 min as detected by EPR 
spectroscopy (Komarov and Lai, unpublished data). On 
the other hand, in the present study, the [(MGD)2-Fe2’] 
complex was injected subcutaneously, where it may dif- 
fuse slowly from the site of injection into the capillary 
bed, and some of the complex binds to *NO generated 
from inducible -NO synthase in the vascular endothelium 
and smooth muscle cells to form the [(MGD),-Fe2’-NO] 
complex prior to entering the blood circulation. Its sus- 
tained accumulation (see Fig. 2) may at least in part be 
due to such a slow release of the [(MGD),-Fe2+] complex 
into the circulation. 
When the [(MGD)2-Fe2’] complex was injected intra- 
venously into the LPS-induced shock mice, the EPR sig- 
nal of the [(MGD),-Fe2+-NO] complex was detected in 
both liver and kidney tissues as shown in Fig. 5a and b, 
respectively, but no signal was detected in blood (Fig. 
5~). The lack of the detectable signal in blood as shown 
in Fig. 5c may be attributable to the inability of the 
intravenously injected [(MGD)2-Fe2’] complex to com- 
pete efficiently for *NO with hemoglobin (20 mM) in red 
cells, which is known to react rapidly with *NO (- 10’ 
M-‘*s-l) to produce nitrate and methemoglobin 
[25]. On the other hand, the [(MGD),-Fe”] complex may 
compete for *NO in tissues where there are far fewer 
scavenging reactions of *NO, as demonstrated in Fig. 5a 
and b. Thus, the different routes by which the [(MGD),- 
Fe”] complex was administrated seemed to affect the 
detectability of the [(MGD),-Fe’+-NO] complex in the 
circulation of LPS-treated mice: while the subcutaneous 
injection produced the detectable [(MGD),-Fe’+-NO] 
signal (Fig. l), the intravenous injection did not (Fig. 5~). 
In summary, we have demonstrated the in vivo real 
time measurement of *NO produced in the circulation of 
the LPS-treated mice by using a newly developed *NO 
spin-trapping method and S-band EPR spectroscopy 
Table 2 
Quantitation of the amounts of the [(MGD),-Fe’+-NO] complex pres- 
ent in various tissues of the LPS-induced shock mice 
Tissue [(MGD)r-Fe”-NO] (nmoUg) 
Liver 36.8 f 5.4 (3)b 
Kidney 10.9 I? 1.6 (3) 
Whole blood 5.4 f 1.4 (3) 
‘The amounts of the [(MGD),-Fe”-NO] complex present in various 
tissues were calculated by comparing the signal intensities obtained 
from the tissues to the signal intensity of a standard solution containing 
0.1 mM of the [(MGD),-Fe*‘-NO] complex in saline solution. 
b The data presented are mean + S.E.M. (number of mice); the amounts 
of [(MGD)2-Fe2C-NO] complex present in the blood of liver and kidney 
tissues as well as the amounts of the blood presented in the wet weights 
of liver and kidney tissues have been corrected [26]. 
124 
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Fig. 5. 3.5 GHz EPR spectra of the [(MGD)s-Fe”-NO] complex in 
various tissues of the septic-shock mice after intravenous injection of 
the [(MGD)2-Fe27 complex. Sii hours after intravenous injection of 
LPS (6 mg; E. cofi 026:B6) through the lateral tail vein, and aliquot 
(0.2 ml) of the [(MGD),-Fe*+] complex in saline was injected intrave- 
nously through the lateral tail vein. The mice were sacrificed 30 min 
after the complex injection, and the isolated (a) liver tissue (88 mg, wet 
weight), (b) kidney tissue (83 mg, wet weight), and(c) heparinized whole 
blood (100 ~1) were transferred into capillary tubes for S-band EPR 
measurement at 22°C. Each of spectra presented here was an average 
of nine 30 s scans. 
[15]. The approach described here should be useful for 
studying the pathogenesis of cytokine-induced and septic 
shock [2]. This new *NO spin-trapping reagent may also 
be suitable for functional EPR imaging or functional 
magnetic resonance imaging of whole animals in various 
pathophysiological conditions where *NO is overpro- 
duced. 
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